Preliminary findings from a national trial of ultrasound as a screening tool in patients at high risk for breast cancer shed light on key variables that influence radiologist interpretive performance.
Preliminary findings from a national trial of ultrasound as a screening tool in patients at high risk for breast cancer shed light on key variables that influence radiologist interpretive performance.
In the first of two studies based on the American College of Radiology Imaging Network 6666 trial and presented at the RSNA meeting on Monday, investigators assessed the impact on interpretive performance of several factors. The factors ranged from breast imaging experience to personal participation in patient scanning.
After a one-hour didactic session on BI-RADS ultrasound categories, 35 radiologists with at least two years of experience in breast imaging reviewed 70 proven cases. The physicians interpreted the cases twice: initially without feedback, and again with immediate feedback based on pathology findings.
Regardless of all other variables, performance improved across the board after feedback, said Dr. Wendie Berg, chief investigator of the ACRIN trial, which is supported by the Avon Foundation and the National Cancer Institute.
But some radiologists performed markedly better than others. The top docs included those who spend at least 25% of their time interpreting breast imaging studies, personally participate in patient scanning, or perform at least 20 to 40 ultrasound exams weekly.
Although radiologists with more experience performed better than those with less, that particular advantage peaks at six to 10 years in breast imaging, Berg said. Performance scores declined in radiologists with 10 or more years of experience.
The lowest performance scores came from radiologists who work at sites where technologists scan patients without any physician involvement.
In a second study based on the ACRIN trial, Berg evaluated radiologists' lesion detection and characterization ability using breast ultrasound. During the study, the team also assessed the impact of specific lesion features on diagnostic performance.
Investigators prepared six phantoms with 17 lesions measuring 2 to 10 mm, placed at different locations and depths. The phantoms were scanned and findings recorded by 66 radiologists at 23 institutions.
Of the 17 lesions, radiologists detected a median of 14 (82%). Larger lesions (5 to 10 mm) were most easily detected, by 97.5% of the radiologists. Detection declined respectively with size, with 83% of radiologists detecting 4-mm lesions, 71% identifying 3-mm lesions, and 44% correctly finding 2-mm lesions.
"Generally, ultrasound sensitivity was highest for lesions 5 to 10 mm," Berg said. "Lesions under 5 mm were less reliably detected and characterized."
Other features influencing detection included lesion depth. The deeper the lesion, the harder the identification, Berg said. Anechoic lesions also posed difficulties: Only 33% of the 3-mm lesions were so characterized.
During the three-year, $8 million ACRIN trial, investigators will study 2508 women at high risk for breast cancer using both mammography and ultrasound. In this initial phase, investigators focused only on interpretive performance factors.
"We expect that performance results using the phantom will be predictive of what we will see in clinical practice, but that will be confirmed once we are further along in the trial," Berg said.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.